31 results about "Plasma mhpg" patented technology

The present invention relates to methods for purifying fibrinogen. In one aspect, the present invention relates to a method of separating fibrinogen from plasma fraction I precipitate. In another aspect, the invention relates to the purification of fibrinogen using ion exchange chromatography.

The invention provides application of HBP protein as a diagnostic marker of Kawasaki disease, and discloses application of HBP protein as a diagnostic marker of Kawasaki disease in preparing diagnostic products of Kawasaki disease and a kit for diagnosing the Kawasaki disease. The experimental results show that the plasma HBP level in acute Kawasaki patients is significantly higher than that in healthy children and general patients infected with fever, the higher HBP concentration is significantly correlated with coronary artery injury in Kawasaki disease, and the HBP level is higher in insensitive patients treated with IVIG than in sensitive patients treated with IVIG. The invention finds that plasma HBP can be used to differentiate Kawasaki disease from infected fever patients, wherein the area under ROC curve (area under the curve, AUC) is 0.88, the optimal diagnostic threshold is 52.5pg/mL, the sensitivity is 88.3%, and the specificity is 74.0%. Therefore, plasma HBP protein of patients can be used as a potential marker for distinguishing diagnosis of Kawasaki disease from infected fever.

The invention discloses a preparation of a platelet washing solution. The platelet washing solution comprises two solutions as follows: 500ml of a bicarbonate Ringer solution and 20-30ml of an ACD-A anticoagulant. The platelet washing solution prepared from 500ml of the bicarbonate Ringer solution and 25ml of the ACD-A anticoagulant is optimal in washing effect. According to the preparation of the platelet washing solution, two solutions with permission to the clinical application at present are mixed at a certain ratio; the platelet washing solution is used for washing and preparing plasma-poor platelet; by virtue of the clinical application of the plasma-poor platelet, the untoward effects of platelet transfusion caused by plasma proteins can be solved. The platelet washing solution is simple in components and liable to depolymerize; the recovery rate of the platelet is increased; the agglomeration force is improved; the safety is guaranteed.

The invention discloses a suspended retransfusion set, and belongs to the technical field of medical equipment and supplies. A clinical washing type autotransfusion technology has allogeneic transfusion shortcomings and plasma protein and coagulation factor loss; a simple method of manual filtering operation by multiple operators is frequently adopted for the conventional filtering type autotransfusion technology, and is exposed and high in pollution rate. The suspended retransfusion set consists of a negative-pressure suction pipeline, a blood recovery pipeline, a retransfusion pipeline and an automatic anticoagulant transfusion device, wherein the negative-pressure suction pipeline consists of a negative-pressure pipe, a negative-pressure conversion bottle, a negative-pressure indicator and a regulator, and is communicated with an upper filter screen gap through an internal opening of the negative-pressure pipe; the blood recovery pipeline comprises a suction head, a blood inlet pipe, a coarse filter screen, a fine filter screen, the upper filter screen gap, a blood storage tank, a blood storage tank air inlet pipe, a blood transfusion three-way valve and the like; the automatic anticoagulant transfusion device comprises a medicine storage tank, a medicine transfusion pipe, a medicine transfusion pipe grading valve, a blood inlet pipe-medicine transfusion pipe synchronization valve and the like. The suspended retransfusion set has the advantages of integrated design, automatic anticoagulant transfusion function, high recovered blood quality, high operability, high emergent treatment performance and the like.

The invention discloses application of a plasma protein composition in preparation of a product for predicting a low-dose radiation irradiation dose. The invention provides the application of a substance for detecting IL-5, IL-12p40 and/or SELP content in blood plasma. The application comprises the following steps of: preparing the product for predicting the low-dose radiation irradiation dose; and preparing products for predicting the number and/or duration of low dose radiation irradiation. The plasma protein composition can be used as an index for predicting the long-term low-dose radiationaccumulated dose, and then the application of the plasma protein composition in predicting the long-term low-dose radiation accumulated dose is provided. The application has important significance indiagnosing the radiation accumulated dose of a radiological worker threatened by long-term low-dose radiation.

In some embodiments, a system and/or method may inhibit and/or ameliorate proteinuria and related comorbidities in a subject. In some embodiments, proteinuria and/or Endothelial Erosion (EE) and related comorbidities may be inhibited and/or ameliorated by maximizing a subject's serum zeta potential. A subject's serum zeta potential may be maximized by administering pharmaceutical compositions which: optimize the negative electrical surface charges of a subject's blood cells, plasma proteins, and/or endothelial surface layer; optimize the composition of a subject's bloodstream (e.g., ionic strength and ion concentrations), and/or optimize the properties of the subject's bloodstream (e.g., serum pH). In some embodiments, Proteinuria and/or EE and related comorbidities may be inhibited and/or ameliorated by: maximizing a subject's serum zeta potential; repairing damage to the endothelial surface layer in a subject; making up for a subject's urinary losses of plasma proteins; and/or optimizing blood flow and facilitating healing of damage caused by Proteinuria and/or EE.

A method for obtaining large volumes of blood from farmed fish especially farmed salmon includes providing a container to which a negative internal pressure is applied. Input tubes to the container include valves to control the flow of fluid into the container through the input tubes. Needles at the distal ends of the tubes are used to access blood vessels of a fish. On opening of the valve associated with the tube connected to the needle accessing the fish blood vessel, the negative pressure in the container draws blood from the fish into the container. Multiple input tubes can be used to access the blood vessels of a corresponding number of fish at the same time to rapidly collect blood from an entire harvest of fish. The method preserves valuable plasma proteins, and prevents contamination of the blood.

The invention provides a device for detecting ultrafiltrate plasma protein of uremia patients after glomerular filtration. The device comprises a body; the upper surface of the inner included angle ofthe side end of the body is fixedly connected to the top surface of a movable plate; clamping shafts are fixedly connected to the top end and the bottom end of the movable plate; the inner sides of the clamping shafts are movably connected to the right ends of movable rods; the inner sides of the movable rods are movably connected to the outer sides of movable shafts; suction stones penetrate through the movable shafts; the bottoms of the movable shafts are slidably connected to the top ends of shelves; and the outer sides of the shelves are fixedly connected to the inner sides of movable pieces. One part of a drying agent will be clamped on the inner side wall of a limiting pipe in an absorbing process, the drying agent which is not clamped can continuously fall to the limiting pipe at the bottom layer by layer to adsorb moisture, and the moisture in the sponge is gradually adsorbed by the drying agent, so that the interior of the machine can be kept dry, the condition of uneven drying area is avoided, inaccurate display is avoided, the reflecting mirror is prevented from becoming dirty, and the accuracy of the light ray rate is guaranteed.

The invention discloses a preparation process and device of low-ash pig plasma protein powder. The preparation process comprises the following steps of S01, carrying out centrifugal separation on pigblood by using a first-stage centrifugal machine; S02, carrying out plasma separation on the pig blood subjected to centrifugal separation by using a separator; S03, carrying out sufficient centrifugal separation on plasma by using a second-stage centrifugal machine; S04, carrying out low-temperature heating on the plasma subjected to sufficient centrifugal separation, and carrying out ultrafiltration concentration on the plasma subjected to low-temperature heating; S05, carrying out spray drying on the plasma subjected to ultrafiltration concentration; S06, keeping the plasma powder subjectedto spray drying dry; and S07, carrying out chromaticity vibration screening on the protein powder subjected to dry keeping, so that the chromaticity of the protein powder is kept on a standard line.According to the preparation process and device, the plasma protein can be fully separated from the blood through first-stage centrifugal separation, separation with the separator and second-stage centrifugal separation, the purity of the plasma protein can be fully improved through ultrafiltration concentration, the gray scale of the plasma protein powder is reduced, and the plasma protein powdercan be made to be in a uniform powder shape through spray drying.

The invention relates to a method for evaluating hypoimmunity of a methamphetamine addict, which comprises the following steps: S1, collecting peripheral venous blood of a subject, and centrifugally separating the peripheral venous blood to obtain plasma; s2, carrying out enzyme-linked immunosorbent assay (ELISA) detection on IL-1beta, S100A8, IFN gamma and ISG15 on the plasma to obtain corresponding plasma protein levels of the IL-1beta, the S100A8, the IFN gamma and the ISG15; and S3, comparing the detected plasma protein levels of the IL-1beta, the S100A8, the IFN gamma and the ISG15 with the plasma protein levels of the IL-1beta, the S100A8, the IFN gamma and the ISG15 of a normal person, and when the detected plasma protein levels are reduced by more than 50% compared with the plasma protein levels of the normal person, considering that the immunity of the subject is reduced and the infection risk is increased. A detection sample is a conventional blood sample, the dosage is small, and sampling is convenient; the detection reagent, the instrument and the detection process are simple and convenient.

Embodiments of the present disclosure relate to a drug monitoring tool. The drug monitoring tool comprises a data receiver and an interactive user interface. The data receiver is configured to receivea pharmacokinetic (PK) profile of a patient. The interactive user interface is configured to display, to the patient, a time-varying therapeutic plasma protein level of the patient. The time-varyingtherapeutic plasma protein level is based on an administered dose of a clotting factor VIII and the PK profile of the patient.